Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Zacks: Analysts Expect Pacira Biosciences Inc (NASDAQ:PCRX) Will Post Earnings of $0.35 Per Share
09:32am, Monday, 20'th Apr 2020
Equities research analysts expect that Pacira Biosciences Inc (NASDAQ:PCRX) will report earnings per share of $0.35 for the current quarter, according to Zacks Investment Research. Nine analysts have
Zacks: Brokerages Anticipate Pacira Biosciences Inc (NASDAQ:PCRX) Will Post Quarterly Sales of $103.10 Million
05:56am, Sunday, 19'th Apr 2020
Equities research analysts expect Pacira Biosciences Inc (NASDAQ:PCRX) to report $103.10 million in sales for the current quarter, Zacks reports. Nine analysts have issued estimates for Pacira Bioscie
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
12:33pm, Friday, 17'th Apr 2020
After Leerink Partners and Piper Sandler gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy, this time
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
12:33pm, Friday, 17'th Apr 2020
After Leerink Partners and Piper Sandler gave Pacira Pharmaceuticals (NASDAQ:
PCRX
) a Buy rating last month, the company received another Buy, this time from Barclays. Analyst
Balaji Prasad
maintaine
Pacira Pharmaceuticals (PCRX) Receives a Buy from Northland Securities
11:38am, Friday, 17'th Apr 2020
Northland Securities analyst Tim Chiang maintained a Buy rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $50.00. The company's
Pacira Pharmaceuticals (PCRX) Receives a Buy from Northland Securities
11:38am, Friday, 17'th Apr 2020
Northland Securities analyst
Tim Chiang
maintained a
Buy
rating on Pacira Pharmaceuticals (
PCRX
–
Research Report
) today and set a price target of
$50.00
. The company’s shares closed last Thurs
StartUPDATES: New developments for healthcare startups
11:30am, Friday, 17'th Apr 2020
Read about new developments at the Airbnb of medical office and surgery center space, HealCo, investment news, and more.
Barclays Remains a Sell on Teva Pharmaceutical Industries (TEVA)
07:01am, Friday, 17'th Apr 2020
Barclays analyst Balaji Prasad maintained a Sell rating on Teva Pharmaceutical Industries (TEVA) yesterday and set a price target of $9.00. The company's
Barclays Remains a Sell on Teva Pharmaceutical Industries (TEVA)
07:01am, Friday, 17'th Apr 2020
Barclays analyst
Balaji Prasad
maintained a
Sell
rating on Teva Pharmaceutical Industries (
TEVA
–
Research Report
) yesterday and set a price target of
$9.00
. The company’s shares closed last Th
Bausch Health Companies (BHC) Gets a Buy Rating from Barclays
07:01am, Friday, 17'th Apr 2020
In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC), with a price target of $28.00. The
Bausch Health Companies (BHC) Gets a Buy Rating from Barclays
07:01am, Friday, 17'th Apr 2020
In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research
RBC Capital Maintains a Hold Rating on Amneal Pharmaceuticals (AMRX)
05:52pm, Thursday, 16'th Apr 2020
In a report released yesterday, Randall Stanicky from RBC Capital maintained a Hold rating on Amneal Pharmaceuticals (AMRX), with a price target of $4.00.
RBC Capital Maintains a Hold Rating on Amneal Pharmaceuticals (AMRX)
05:52pm, Thursday, 16'th Apr 2020
In a report released yesterday,
Randall Stanicky
from RBC Capital maintained a
Hold
rating on Amneal Pharmaceuticals (
AMRX
–
Research Report
), with a price target of
$4.00
. The company’s shares
Stifel Nicolaus Keeps Their Buy Rating on Urogen Pharma (URGN)
10:10pm, Wednesday, 15'th Apr 2020
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Urogen Pharma (URGN). The company's shares closed last Wednesday
Stifel Nicolaus Keeps Their Buy Rating on Urogen Pharma (URGN)
10:10pm, Wednesday, 15'th Apr 2020
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Urogen Pharma (URGN – Research
